Somatic mutations in KEAP1 and NRF2 occur in a variety of cancer types and are important mediators of aberrant anti-oxidant responses [39, 40]; however, no such mutations have been reported to date in human leukemia cells (The Cancer Genome Atlas, TCGA, database) [41–43]. This evidence concerns the gene NFE2L2 and cancer.